Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily : Two-year follow-up of a randomized phase 2 study (START-R)

✍ Scribed by Hagop Kantarjian; Ricardo Pasquini; Vincent Lévy; Saengsuree Jootar; Jerzy Holowiecki; Nelson Hamerschlak; Timothy Hughes; Eric Bleickardt; David Dejardin; Jorge Cortes; Neil P. Shah

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 297 KB
• Volume: 115
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.24504